FDA approves first biosimilar drug for cancer
(HealthDay)—The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration.
Sep 15, 2017
0
2
(HealthDay)—The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration.
Sep 15, 2017
0
2
Comparing levels of specific proteins that the drug Avastin targets could identify patients with advanced bowel cancer who will benefit from the treatment, according to research published in Clinical Cancer Research.
Oct 23, 2012
0
0
New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts ...
Feb 12, 2013
0
0
The French competition authority (AFC) on Thursday slapped a record 444 million euro ($500 million) fine on pharma groups Novartis, Roche and Genentech over market abuses in sales of macular degeneration drugs.
Sep 9, 2020
0
3
Swiss drugmaker Roche said Friday that the Food and Drug Administration approved its drug Avastin as a treatment for ovarian cancer.
Nov 14, 2014
0
0
(HealthDay)—The drug Avastin (bevacizumab), when added to chemotherapy, does not improve disease-free survival in patients with triple-negative breast cancer any better than chemo alone, new research finds.
Dec 7, 2012
0
0
A new cervical cancer drug offers the first good hope of extending life for women with advanced stages of the disease, according to a study published Sunday.
Jun 2, 2013
0
0
(AP)—The Food and Drug Administration is warning doctors that a compounding pharmacy is recalling syringes of the Roche drug Avastin after receiving reports of eye infections among patients.
Mar 20, 2013
0
0
(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).
Apr 24, 2012
0
0
VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might potentially predict which patients will benefit more from treatment with bevacizumab (Avastin). If validated, this discovery ...
May 21, 2012
0
0